FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer
© Qiu et al.; licensee BioMed Central Ltd. 2014
Received: 17 December 2013
Accepted: 6 February 2014
Published: 11 February 2014
Increasing evidence suggests that forkhead box A1 (FOXA1) is frequently dysregulated in many types of human cancers. However, the exact function and mechanism of FOXA1 in human endometrial cancer (EC) remains unclear.
FOXA1 expression, androgen receptor (AR) expression, and the relationships of these two markers with clinicopathological factors were determined by immunohistochemistry analysis. FOXA1 and AR were up-regulated by transient transfection with plasmids, and were down-regulated by transfection with siRNA or short hairpin RNA (shRNA). The effects of FOXA1 depletion and FOXA1 overexpression on AR-mediated transcription as well as Notch pathway and their impact on EC cell proliferation were examined by qRT-PCR, western blotting, co-immunoprecipitation, ChIP-PCR, MTT, colony-formation, and xenograft tumor–formation assays.
We found that the expression of FOXA1 and AR in ECs was significantly higher than that in a typical hyperplasia and normal tissues. FOXA1 expression was significantly correlated with AR expression in clinical tissues. High FOXA1 levels positively correlated with pathological grade and depth of myometrial invasion in EC. High AR levels also positively correlated with pathological grade in EC. Moreover, the expression of XBP1, MYC, ZBTB16, and UHRF1, which are downstream targets of AR, was promoted by FOXA1 up-regulation or inhibited by FOXA1 down-regulation. Co-immunoprecipitation showed that FOXA1 interacted with AR in EC cells. ChIP-PCR assays showed that FOXA1 and AR could directly bind to the promoter and enhancer regions upstream of MYC. Mechanistic investigation revealed that over-expression of Notch1 and Hes1 proteins by FOXA1 could be reversed by AR depletion. In addition, we showed that down-regulation of AR attenuated FOXA1-up-regulated cell proliferation. However, AR didn’t influence the promotion effect of FOXA1 on cell migration and invasion. In vivo xenograft model, FOXA1 knockdown reduced the rate of tumor growth.
These results suggest that FOXA1 promotes cell proliferation by AR and activates Notch pathway. It indicated that FOXA1 and AR may serve as potential gene therapy in EC.
KeywordsEndometrial cancer FOXA1 AR Proliferation Notch pathway
Endometrial cancer (EC) is one of the most common gynecologic malignancies. The incidence of EC has markedly increased in recent years. EC is broadly classified into two groups ; type I ECs are linked to estrogen excess, hormone-receptor positivity, and favorable prognoses, whereas type II, primarily serous tumors, are more common in older women and have poorer outcomes . Primary treatment, including surgery and radiation, cannot provide sufficient tumor control, especially in high-grade, undifferentiated tumors with deep muscle infiltration. Endocrine treatment, including medroxyprogesterone acetate or tamoxifen, is sometimes useful to improve the outcome. However, patients with type II EC and even some patients with type I EC are refractory to traditional endocrine treatment . Thus, a new treatment is needed to achieve a better response.
Several studies have shown that the majority of ECs also express another hormone receptor, androgen receptor (AR) [4, 5]. The results of immunohistochemical analysis indicate that, compared with endometrial glandular epithelial cells in normal cycling endometrium, more epithelial cells express AR in ECs . Moreover, in female mice, in contrast to AR−/− uteri, AR+/+ uteri have uterine hypertrophy and endometrial growth . It thus is very important to examine the possible actions and metabolism mediated by AR in human EC.
Forkhead box A1 (FOXA1) is a transcription factor that belongs to the forkhead family consisting of the winged-helix DNA-binding domain and the N-terminal and C-terminal transcriptional domains. FOXA1 is expressed in various organs, including breast, liver, pancreas, and prostate, and can influence the expression of a large number of genes associated with metabolic processes, regulation of signaling, and the cell cycle [7, 8]. FOXA1 has been identified as a “pioneer factor” that binds to chromatin-packaged DNA and opens the chromatin for binding of additional transcription factors, including AR . FOXA1 also binds directly to AR and regulates transcription of prostate-specific genes in prostate cancer . Recent global gene expression studies of prostate cancer and triple-negative breast cancer have shown that high FOXA1 expression, which correlates positively with AR level, promotes tumor proliferation [11, 12]. Thus, FOXA1 expression is considered a predictor of poor survival in prostate cancer and triple-negative breast cancer. However, the interaction between FOXA1 and AR in EC remains unclear.
An aberrant Notch pathway has been documented in various cancer types and has been associated with tumorigenesis [13–15]. The Notch pathway is initiated by ligand binding, which is followed by intramembranous proteolytic cleavage of the Notch1 receptor to release an active form of the Notch intracellular domain (NICD). The NICD subsequently translocates to the nucleus and acts as a transcriptional activator to enhance the expression of target genes such as Hairy-enhancer of split1 (Hes1) . Abnormal activation of the Notch pathway promotes proliferation in a variety of cancer cell types, including EC [15, 17].
In the present study, we investigated the dependency of AR on FOXA1 expression in tissue paraffin sections, in multiple cellular contexts, and on tumor-bearing nude mice. Here we show, for the first time, that FOXA1 activates the Notch pathway through AR and that AR is required for FOXA1-enhanced cell proliferation in EC.
Patients and tissues
The relationship between protein expression and clinicopathological features in EC
Papillary serous carcinoma
Lymph node metastasis
Depth of myometrial invasion
Staining was performed on paraffin-embedded specimens using primary antibodies as follows: anti-FOXA1 (1:200; Abcam, Cambridge, MA, USA) and anti-AR (1:50; Abcam). The percentage of positively stained cells was rated as follows: 0 point = 0%, 1 point = 1% to 25%, 2 points = 26% to 50%, 3 points = 51% to 75%, and 4 points = greater than 75%. The staining intensity was rated in the following manner: 0 points = negative staining, 1 point = weak intensity, 2 points = moderate intensity, and 3 points = strong intensity. Then, immunoreactivity scores for each case were obtained by multiplying the values of the two parameters described above. The average score for all of five random fields at 200× magnification was used as the histological score (HS). Tumors were categorized into two groups based on the HS: low-expression group (HS = 0–5) and high-expression group (HS = 6–12).
Cell culture and experimental setup
The human endometrial cell lines AN3CA, RL95-2, and HEC-1B were obtained from the Chinese Academy of Sciences Committee Type Culture Collection cell bank. These three cell lines were grown in Dulbecco’s modified Eagle’s medium (DMEM)/F12 (HyClone, Waltham, MA, USA) supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA, USA) in a humidified atmosphere of 5% CO2 at 37°C. The human endometrial cell line MFE-296 was purchased from Sigma (St. Louis, MO, USA). The MFE-296 cell line was grown in high-glucose DMEM (4.5 g/L glucose) (HyClone) supplemented with 10% fetal bovine serum in a humidified atmosphere of 5% CO2 at 37°C.
To investigate the impact of FOXA1 on the AR-mediated transcription, the AR pathway agonist 5α-dihydrotestosterone (DHT) (Dr. Ehrenstorfer, Augsburg, Germany) and the AR pathway blocker flutamide (Sigma) were purchased and dissolved in 100% ethanol for storage. In this study they were diluted with phenol red–free DMEM/F12 (Gibco) immediately before each experiment, with the final concentration of ethanol at 0.1%. DHT was added into the cell culture media at concentrations of 10−9 to 10−7 M for different periods (0–48 h). To block the activation of AR-mediated transcription, flutamide (10−6 M) was added into the media 30 min before DHT. Vehicle contained 0.1% absolute ethanol/phenol red–free DMEM/F12.
To stably knock down endogenous FOXA1 expression, MFE-296 cells were grown to 30% confluency in 6-well culture plates and then infected with lentivirus carrying an shRNA targeting FOXA1 (shFOXA1) or a negative control vector (NC; LV3-pGLV-h1-GFP-puro vector, D03004; GenePharma, Shanghai, China) at a multiplicity of infection of 70 in the presence of polybrene (8 μg/mL). After 48 h of infection at 37°C, the medium was replaced with fresh medium and incubated further for 72 h before analysis using quantitative RT-PCR (qRT-PCR) and western blotting for FOXA1 expression. The shRNA sequences used were 5′-GAGAGAAAAAAUCAACAGC-3′ (shFOXA1) and 5′-TTCTCCGAACGTGTCACGT-3′ (NC).
The plasmid PWP1/GFP/Neo-AR containing transfection-ready AR cDNA (exAR) and its negative control PWP1/GFP/Neo were gifts from Doctor Yuyang Zhao at Shanghai First People’s Hospital. MFE-296 cells stably transfected with shFOXA1 or NC were transiently cotransfected with PWP1/GFP/Neo-AR (exAR) or its negative control (NC). The plasmid pCMV/3FLAG/Neo-FOXA1 containing transfection-ready FOXA1 cDNA (exFOXA1) (GenBank: BC033890) and a pure pCMV/3FLAG/Neo (NC) were purchased from Genechem (Product code: GOSE33403; Shanghai, China). AN3CA cells were transiently transfected with exFOXA1 or NC or cotransfected with a siRNA targeting AR (siAR) (Genephama Biotech, Shanghai, China) or its negative control (NC) in Opti-MEM (Invitrogen, Carlsbad, CA, USA) using Lipo2000 (Invitrogen). The siRNA targeting FOXA1 (siFOXA1) and its negative control (NC) were purchased from Genephama Biotech (Shanghai, China). AN3CA cells were transiently transfected with exAR or NC or cotransfected with siFOXA1 or NC in Opti-MEM (Invitrogen) using Lipo2000 (Invitrogen). The transfection solution was removed from the cells and replaced with standard medium after 8 h. The sequences of the siRNA oligos used were: siAR: sense: 5′-AUGUCAACUCCAGGAUGCUTT-3′, antisense: 5′-AGCAUCCUGGAGUUGACAUTT-3′; siFOXA1: sense: 5′-GAGAGAAAAAAUCAACAGC-3′, antisense: 5′-GCUGUUGAUUUUUUCUCUC-3′.
Total RNA was extracted from cultured cells by Trizol Reagent (Invitrogen). RNA was converted to cDNA with the one-step Prime Script RT reagent kit (TaKaRa, Dalian, China), and the cDNA was analyzed by real-time PCR using SYBR Premix Ex Taq (TaKaRa) in an Eppendorf Mastercycler® realplex. Each sample was assayed in triplicate in each of three independent experiments. All values are expressed as mean ± standard deviation. The following primers were used: FOXA1: sense: 5′-AGGTGTGTATTCCAGACCCG-3′, antisense: 5′-TTGACGGTTTGGTTTGTGTG-3′; AR: sense: 5′-CCTGGCTTCCGCAACTTACAC-3′, antisense: 3′-GGACTTGTGCATGCGGTACTCA-5′; MYC: sense: 5′-AAAGGCCCCCAAGGTAGTTA-3′, antisense: 5′-TTTCCGCAACAAGTCCTCTT-3′; XBP1: sense: 5′-CCTTGTAGTTGAGAACCAGG-3′, antisense: 5′-GGGGCTTGGTATATATGTGG-3′; UHRF1: sense: 5′-AAGGTGGAGCCCTACAGTCTC-3′, antisense: 5′-CACTTTACTCAGGAACAACTGGAAC-3′; and ZBTB16: sense: 5′-CCAGCAGATTCTGGAGTATGCA-3′, antisense: 5′-GCATACAGCAGGTCATCCAAGTC-3′.
Total protein was extracted using a RIPA kit (Beyotime, Shanghai, China) containing a 1% dilution of the protease inhibitor PMSF (Beyotime). Protein concentrations were determined by the enhanced BCA Protein Assay kit (Beyotime). Equal amounts of protein in each lane were separated by 8% SDS-PAGE and transferred to a PVDF membrane (Millipore, Billerica, MA, USA). After blocking the membrane in blocking buffer (5% milk powder in 20 mM Tris–HCl pH 7.5, 500 mM NaCl, 0.1% (v/v) Tween 20), the membrane was incubated with primary antibodies against FOXA1 (1:1000; Abcam), AR (1:2000; Cell Signaling Technology, Danvers, MA, USA), Notch1 (1:2000; Epitomics, Burlingame, CA, USA), Hes1 (1:2000; Epitomics), and β-actin (1:2000, Cell Signaling Technology) at 4°C overnight. Peroxidase-linked secondary anti-rabbit or anti-mouse antibodies were used to detect the bound primary antibodies.
Total protein was extracted from cells treated or not treated with 10−7 M DHT for 24 h (described in the Cell culture and experimental setup section). After protein quantification, 500 μg of each cell lysate was added to 10 μl of anti-FOXA1 (Epitomics) and shaken at 4°C overnight, then added to 30 μl of Protein A + G Agarose (Beyotime), shaken at 4°C for 4 h, centrifuged at 2500 × g for 5 min, and washed with a RIPA kit (Beyotime) to collect the immunoprecipitate-bound agarose beads. Each immunoprecipitate was denatured with 20 μl of 1× SDS-PAGE loading buffer at 100°C for 5 min. Each supernatant was subjected to SDS-PAGE (8% acrylamide). It is important to note that FOXA1 (51 kDa) is close in size to IgG (55 kDa). To avoid detecting IgG protein left from the immunoprecipitation process and FOXA1 protein from the same species in the western blot at the same time, we used anti-FOXA1 from mouse in western blotting, whereas anti-FOXA1 from rabbit was used for immunoprecipitation. Primary antibodies against AR (1:2000) and FOXA1 (1:500; Santa Cruz Biotechnology, Dallas, TX, USA) were used for western blotting. Other steps were as described in the Western blotting section.
Chromatin immunoprecipitation (ChIP)-PCR
Chromatin immunoprecipitation (ChIP) assays were performed as previously described  using anti-FOXA1 antibody (ab23738, Abcam), anti-AR antibody (sc-7305, Santa Cruz Biotechnology). FOXA1-AR overlapping binding sites were identified by Chip-seq as previously depicted  and by qRT-PCR using SYBR Premix Ex Taq (Takara). Enrichment was calculated using the comparative Ct method, and was analyzed for specificity, linearity range, and efficiency in order to accurately evaluate the occupancy (percentage of immunoprecipitation/input). IgG was used as negative control. The primers used included: MYC pro: sense: 5′-CCCCCGAATTGTTTTCTCTT-3′, antisense: 5′-TCTCATCCTTGGTCCCTCAC-3′; MYC enh-1: sense: 5′-AGACAGAGGCAGGGTGGAG-3′, antisense: 3′-CCCAGGTAAACAGCCAATGT-5′; MYC enh-2a: sense: 5′-CCGTTCCGTGTCTAACCACT-3′, antisense: 5′-ATGAAACTCGGGGAGTGTTG-3′; MYC enh-2b: sense: 5′-AGCGTTCTCTTTGCCAGAAA-3′, antisense: 3′-GGCAAAGCTTCACAGAGGAC-5′; MYC enh-2c: sense: 5′-CACACAAGAAGAGCAAACTGAAG-3′, antisense: 5′-TGAGGATTGTTAGGAATCTCTGG-3′.
Cells (3 × 103 cells/well) were plated in 96-well plates. Then, 20 μl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 5 mg/ml; Sigma) was added to each well and subsequently incubated at 37°C for 4 h. The absorbance at 490 nm was then measured using a microplate reader. Cells incubated with culture medium were used as a control group. Each sample was assayed in triplicate.
Cell lines were trypsinized to generate a single-cell suspension, and 120 cells/well (MFE-296 cells) or 200 cells/well (AN3CA cells) were seeded into 6-well plates. Dishes were returned to the incubator for 14 days, and the colonies were fixed with methanol for 30 min at room temperature and then stained with 0.5% crystal violet for 1 h.
Cell migration and invasion assays
Cells were trypsinized, centrifuged, and resuspended in serum-free medium. Cells were then plated at a density of 1 × 105/well (for the migration assay) or 2 × 105/well (for the invasion assay) in invasion chambers (8 μm pore size; BD Biosciences, California, USA) with or without matrigel coating for invasion and migration assays. Complete medium (600 μl) was added to the lower chamber as a chemoattractant. After incubation for 5 h (MFE-296) or 24 h (AN3CA) for the migration assay, or after incubation for 24 h (MFE-296) or 48 h (AN3CA) for the invasion assay, cells were fixed with 4% paraformaldehyde for 1 h. Cells on the apical side of each insert were removed by mechanical scraping. Cells that migrated to the basal side of the membrane were stained with 0.5% crystal violet and counted at 200× magnification. The migration and invasion assays were repeated at least three times.
Xenograft tumor–formation assays
Female athymic mice of 4 weeks of age were obtained from the Shanghai Experimental Animal Center of the Chinese Academy of Science. Our animal research was carried out in strict accordance with the recommendations in the Guideline for the Care and Use of Laboratory Animals of China. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Obstetrical and Gynecological Hospital affiliated Fudan University (Permit Number: SYXK (hu) 2008–0064). All efforts were made to minimize animal suffering.
To establish a nude mouse model bearing EC, uninfected MFE-296 cells (MFE-296), stable MFE-296 cells infected with lentivirus carrying shFOXA1 (MFE-296/shFOXA1) or vector alone (MFE-296/NC) were used. All mice were randomly divided into three groups of four mice. Each mouse was given a unilateral subcutaneous injection of 1 × 107 cells. Tumor measurement began one week after injection and was conducted weekly using digital calipers. The tumors were removed and weighed after 42 days. Tumor volume was calculated as follows: tumor volume (cm3) = (the longest diameter) × (the shortest diameter)2 × 0.5.
Immunohistochemical staining of mouse tumor samples
Tumor samples from xenografted mice were collected and fixed according to routine procedures. Histological staining was then performed on the tissue sections of the paraffin-embedded tumors using the streptavidin-biotin-peroxidase method. Primary antibodies were as follows: anti-FOXA1 (1:200; Abcam), anti-AR (1:50, Abcam), anti-Notch1 (1:100; Epitomics,), anti-Hes1 (1:250; Epitomics), anti-Ki67 (1:100; Boster, Wuhan, China), and anti-PCNA (1:100; Boster). The sections were then counterstained with hematoxylin and eosin (H&E).
Measured data were assessed by unpaired Student’s t-test or one-way ANOVA for multiple comparisons, and χ2 test for 2 × 2 tables was used to compare the categorical data. p < 0.05 was considered significant.
Expression of FOXA1 and AR in endometrial tissues and the clinicopathological significance in EC specimens
Immunohistochemical analysis of protein expression in different endometrial tissues
FOXA1 affects AR expression in human EC cells
We next manipulated FOXA1 expression and examined its influence on AR expression. AN3CA cells were transiently transfected with a FOXA1 plasmid to overexpress FOXA1 (AN3CA/exFOXA1) or with control vector (AN3CA/NC). Moreover, to knock down FOXA1 expression, MFE-296 cells were stably transfected with FOXA1 shRNA (MFE-296/shFOXA1) or control vector (MFE-296/NC) (Figure 2B). AR expression was then analyzed by qRT-PCR and western blotting, which showed that the AR level was significantly enhanced by FOXA1 overexpression and reduced by FOXA1 depletion (Figure 2C–H). Together, the data suggested that FOXA1 affected the AR level in EC cells.
FOXA1 expression affects AR target gene expression in human EC cells
To investigate whether FOXA1 influences AR-mediated transcription, we transfected hormone-deprived EC cells with shFOXA1, exFOXA1, or the appropriate negative control vector and then treated them with vehicle or DHT for 24 h. In MFE-296/NC cells, DHT caused a ≥10-fold increase in the expression of the four AR-regulated genes compared with the MFE-296/NC cells treated with vehicle. When FOXA1 expression was knocked down in MFE-296 cells transfected with shFOXA1, however, the expression of these genes was not as markedly increased, and their expression decreased by 8- to 20-fold after treatment with DHT (Figure 3D). Moreover, we found that the increase in the expression of AR and AR-regulated genes was remarkably greater by DHT in the AN3CA/exFOXA1 cells compared with the AN3CA/NC cells (Figure 3E). Our findings indicated that FOXA1 expression globally affected AR-mediated transcription, with all of the four AR-regulated genes requiring FOXA1 for appropriate AR-mediated regulation.
FOXA1 promotes AR target gene expression by interaction with AR
FOXA1 can target a series of transcription factors representing anywhere from several to hundreds of genes. To address whether the effects of FOXA1 on AR downstream targets are primarily through upregulating AR, rather than upregulating AR downstream targets directly, we used untransfected MFE-296 cells (MFE-296) and MFE-296 cells transfected with shFOXA1 (MFE-296/shFOXA1), NC (MFE-296/NC), or shFOXA1 together with exAR (MFE-296/shFOXA1 + exAR). qRT-PCR and western blotting analysis confirmed that transfection of exAR resulted in overexpression of AR (Figure 3F). qRT-PCR verified that MFE-296/shFOXA1 cells exhibited substantial decreases in the four AR targets compared with MFE-296/NC cells (Figure 3G). Furthermore, cotransfection with exAR rescued the inhibited expression of the target genes caused by FOXA1 downregulation in MFE-296/shFOXA1 cells (Figure 3G). In addition, we used untransfected AN3CA cells (AN3CA) and AN3CA cells transfected with NC (AN3CA/NC), exFOXA1 (AN3CA/exFOXA1), or exFOXA1 together with siAR (AN3CA/exFOXA1 + siAR). qRT-PCR and western blotting analysis confirmed that transfection with siAR resulted in silencing of AR (Figure 3H). Overexpression of FOXA1 increased the expression of the four AR target genes. Moreover, cotransfection with siAR partially reversed the FOXA1-induced overexpression (Figure 3I). These results verified that AR downregulation attenuated the effect of FOXA1 on AR-mediated transcription and suggested that FOXA1 might promote AR downstream targets at least in part through AR.
FOXA1 and AR are found in the same protein complex
We further examined whether FOXA1 and AR could bind to the five putative FOXA1-AR binding regions, including the promoter and enhancer regions upstream of the TSS (transcription start sites) of AR target genes such as MYC (Figure 4C). Our ChIP assays showed that both FOXA1 and AR could bind to all the five putative FOXA1-AR-binding regions in MFE-296 cells. Moreover, both FOXA1 and AR bound most greatly to the Enh-1 (enhancer 1) region among the five binding regions (Figure 4D). Our ChIP data together with our co-immunoprecipitation data suggested that FOXA1 forming protein complex with AR might bind to FOXA1-AR overlapping binding regions upstream of MYC, leading to MYC activation in EC cells.
AR is required for FOXA1-enhanced Notch pathway activation of EC cells
Pathway analysis in liver cancer shows that FOXA1/AR dual target genes are most involved in the cellular growth/proliferation pathway . Notch pathway activation appears to affect proliferation in many cancers. In EC, the Notch pathway has also been shown to be involved in cell proliferation . Thus, we considered that the interaction between FOXA1 and AR might be related with the Notch pathway. We used western blot analysis to assess the levels of Notch1 and the Notch pathway target protein, Hes1, in MFE-296/shFOXA1 and AN3CA/exFOXA1 cells after exAR or siAR cotransfection, respectively. Cotransfection with exAR rescued the decreased expression of Notch1 and Hes1 caused by FOXA1 downregulation in MFE-296/shFOXA1 cells (Figure 4E). Furthermore, cotransfection with siAR attenuated the increased expression of Notch1 and Hes1 caused by upregulation of FOXA1 in AN3CA/exFOXA1 cells (Figure 4F). These results suggested that the effects of FOXA1 on Notch pathway activation were mediated by AR. In order to determine whether AR was required for FOXA1-enhanced Notch pathway activation, we over-expressed AR expression in AN3CA cells, which has low level of AR. We assessed the levels of Notch1 and Hes1 in untransfected AN3CA cells (AN3CA) as well as AN3CA cells transfected with NC (AN3CA/NC), exAR (AN3CA/exAR), or exAR together with siFOXA1 (AN3CA/exAR + siFOXA1). AN3CA/exAR cells exhibited a substantial increase in AR expression as compared to AN3CA/NC cells, accompanied by over-expression of Notch1 and Hes1 (Additional file 3: Figure S1). Furthermore, cotransfection with siFOXA1 did not rescue the activation of Notch1 and Hes1 caused by AR upregulation in AN3CA/exAR cells (Additional file 3: Figure S1). These results suggested a mechanism, where AR might be a necessary medium in FOXA1-enhanced Notch pathway activation in AN3CA cells.
FOXA1 promotes proliferation of human EC cells
AR is required for FOXA1-enhanced proliferation of EC cells
To directly address whether the effects of FOXA1 in promoting EC cell proliferation can be attributed to its activation of AR, a rescue experiment in MFE-296 cells was performed. In the colony-forming assay, cotransfection with exAR rescued the decreased rate of cell growth caused by FOXA1 downregulation in shFOXA1 cells (Figure 5E). The MTT assay also showed that cotransfection with exAR rescued the inhibition of cell viability caused by FOXA1 downregulation in shFOXA1 cells (Figure 5F). The similarity of results from the colony-forming and MTT assays suggested that the effects of FOXA1 in mediating cell proliferation of EC cells were mediated through AR.
AR is not required for FOXA1-enhanced migration and invasion of EC cells
Consistent with these findings, the invasion rate was significantly reduced in MFE-296/shFOXA1 cells, but the reduction was not reversed upon transfection with exAR (Figure 6C). Likewise, the invasion rate was enhanced in AN3CA/exFOXA1 cells, but this enhancement was not attenuated upon transfection with siAR (Figure 6D). These results demonstrated a functional role for FOXA1 in mediating migration and invasion in EC cells and suggested a mechanism (distinct from that for EC cell proliferation) by which AR might not contribute to FOXA1-mediated metastasis of EC.
Oncogenic role of FOXA1 in a tumor xenograft model
Over the past decade, FOXA1 expression has been examined in several human cancers, and oncogenic and tumor-suppressive roles have been proposed for FOXA1 depending on the cancer type and, in some cases, the subtype. In acute myelocytic leukemia, esophageal squamous cell carcinomas, lung adenocarcinomas, thyroid carcinoma, prostate cancer, and AR-positive molecular apocrine breast cancer [12, 23–25], FOXA1 acts as an oncogene. However, in hepatocellular carcinoma, pancreatic, and estrogen receptor (ER)-positive breast cancer, FOXA1 has been reported to have a tumor-suppressive function [26–28]. On one hand, FOXA1 acts as a tumor oncogene. In oesophageal squamous cell carcinoma, FOXA1 expression is correlated with lymph node metastases in immunohistochemical specimens and FOXA1 expression inhibition decreases cellular invasion and migration . Also, FOXA1 is over-expressed in aggressive thyroid cancers (ATC) and involved in cell cycle progression via down-regulation of p27Kip1 in an ATC cell line . On the other hand, FOXA1 has been reported to act as a tumor suppressor. It has been reported that FOXA1 positively regulates miRNA-122, which is correlated with favourable prognosis in human hepatocellular carcinoma . In addition, FOXA1 acts as an important antagonist of the epithelial-to-mesenchymal transition (EMT) in pancreatic ductal adenocarcinoma through its positive regulation of E-cadherin and maintenance of the epithelial phenotype . It is critical to note that the role of FOXA1, as a tumor oncogene or a tumor suppressor gene, has been reported to vary in prostate and breast cancers depending on multiple cancer subtypes and states of hormone dependence or independence [11, 12, 28].
A previous study has addressed the expression and function of FOXA1 in EC; immunohistochemical analysis by Abe et al. indicated that FOXA1 was negatively associated with lymph node status in EC immunohistochemical specimens in Japanese, and FOXA1 repressed proliferation and migration in one type of EC cells (Ishikawa) . However, our study found that the FOXA1 level in ECs was significantly higher than that in atypical hyperplasia and normal tissues (p < 0.05) in immunohistochemical specimens and that FOXA1 promoted tumor cell proliferation in EC, which differs from the previous results. The difference might be attributed to the immunohistochemical samples in different countries used. Alternatively, the cancer subtype may affect the results: the function of FOXA1 as a tumor suppressor in the Abe et al. study was investigated in the Ishikawa cell line, which is ER-positive , whereas we used MFE-296 (high levels of FOXA1 and AR) and AN3CA (low levels of FOXA1 and AR), which are both ER-negative cell lines [33, 34]. This idea consists with breast cancer studies that have shown that FOXA1 functions as a tumor suppressor in ER-positive breast cancer cells (MCF-7)  but as a tumor activator in ER-negative breast cancer cells (MDA-MB-453) . Furthermore, this idea of the effects of forkhead family members depending on ER expression is also consistent with the study that have shown the Forkhead box class o 3a transcription factor (FoxO3a) has inhibitory effects on motility and invasiveness of ER-positive breast cancer cells but inducing effects on motility and invasiveness of ER-negative breast cancer cells . More comprehensive studies covering several EC cell lines in different cancer subtypes will be necessary to define the role of FOXA1 in EC development.
Most researches on hormone receptors in EC have focused on ER and progesterone receptor (PR). However, the expression of AR in the human normal endometrium and its disorders is not well understood. Though higher serum androgen levels have been certified to exist in the utero-ovarian vein blood samples from women with EC , the details of AR expression and its actions in EC are a topic of dispute. Longer CAG repeats in AR promote carcinogenesis of uterine endometrial cells . Androgens and AR may be involved in endometrial cell proliferation by regulating the expression of insulin growth factor I (IGF-I) in the uterus . Our results suggest that AR expression is significantly higher in EC than in normal endometrium and that AR activated by FOXA1 might promote the Notch pathway, which may be another mechanism involving AR in EC.
Most FOXA1 studies have focused on its role as a pioneer factor that binds to DNA packaged in chromatin and opens the chromatin for binding of additional transcription factors including AR [39, 40]. According to our results from qRT-PCR and western blotting, FOXA1 regulates AR target genes by up-regulation of AR expression. Interestingly, our co-immunoprecipitation results (Figure 4A and 4B) showed that FOXA1 interacted with AR at the protein level. Apart from that, our ChIP-PCR results suggested that FOXA1 and AR were directly bound to the same regions upstream of MYC (Figure 4C and 4D). Based on the above results, we suggest that FOXA1 may also directly regulate AR target genes (at least MYC) by binding to AR in EC. Our results regarding an interaction between AR and FOXA1 may be related to the finding that the AR and FOXA1 binding sites are adjacent on multiple promoters of AR target genes in prostatic cells [9, 41]. Thus, FOXA1 may regulate the AR target genes through at least two means: AR over-expression or physical interaction with AR in order to induce easy AR accessibility to binding to its target genes. MYC is an immediate early response gene downstream from AR pathway and is tightly regulated through AR cis-regulatory elements identified within its proximal promoters and distal enhancer regions , which is consistent with our ChIP-PCR results (Figure 4C and 4D). Interestingly, we showed that FOXA1 and AR more evidently bound to the MYC enhancer regions as compared to MYC promoter regions. These results could be attributed to other co-regulators involved in this binding process. Since TCF7L2, a protein mediating DNA looping for long-distance interactions of distal enhancers and proximal promoters, physically interacts with FOXA1 and AR and mediates the transcription of MYC in breast cancer , future investigation will be needed to clarify which co-regulators are involved in FOXA1/AR binding to the enhancer regions upstream of MYC in EC cells.
Although the underlying mechanisms governing the FOXA1-AR correlation in tumor progression are not fully understood, a pathway analysis showed that 187 FOXA1/AR dual target genes were involved in the cellular growth/proliferation pathway in liver cancer . The Notch pathway is implicated in the development of various cancers, and the Notch pathway blockade appears to affect cell proliferation in multiple types of cancers. Notch pathway inhibition in breast cancer cells induces cell cycle arrest and apoptosis . Similarly, downregulation of Notch1 contributes to cell growth inhibition in pancreatic cancer . Our results suggest that downregulation of AR attenuated FOXA1-induced upregulation of the Notch pathway in EC cells. These findings indicate that FOXA1 might promote AR-mediated transcription and ultimately activate the Notch pathway. Here, we describe, for the first time, the association between FOXA1 expression and the Notch pathway in cancer.
The specific mechanism of cell proliferation in EC reported so far has been limited, although several classical transcription factors related to proliferation have been identified, including cyclin D1, p53, IGFBP-1, PTEN, and p27Kip1[44–48]. In this study, we suggest that FOXA1 promotes cell proliferation in EC by interaction with AR, possibly via the Notch pathway, which may be a newly identified regulatory mechanism of cell proliferation in EC.
We further investigated the effects of FOXA1 and AR on migration and invasion of EC cells, and found that neutralization of AR activity did not inhibit FOXA1-enhanced cancer cell migration or invasion. These observations indicate that the promoting effect of FOXA1 on migration and invasion is not dependent on AR. Our findings in migration and invasion assays are consistent with our findings in immunohistochemical staining, which showed that higher expression of FOXA1 but not AR is found in tumors that displayed a greater depth of myometrial invasion. These results suggest that AR is not the only downstream target of FOXA1 in EC. Future studies will be necessary to define which transcription factors or pathways are involved in FOXA1-enhanced cell migration and invasion in EC.
The traditional endocrine treatment (mainly targeting ER and PR) is ineffective in most ER-negative and PR-negative ECs, and even in some ER-positive and PR-positive ECs . In our investigation, 9 of the15 ER-negative EC cases (60.0%) and 41 of the 61 ER-positive EC cases (67.2%) were AR positive, and the majority of ECs were also FOXA1 positive (Table 1). Thus, AR and FOXA1 might be alternative targets in ECs insensitive to traditional endocrine treatment or could be targets for adjuvant treatment following surgery and traditional endocrine treatment. There has been speculation about the use of anti-androgens for the treatment of ECs ; this hypothesis warrants clinical investigation in light of our findings.
In summary, our results suggest a new mechanism for the development of EC, in which FOXA1 promotes tumor cell proliferation through AR and activates the Notch pathway by influencing AR expression. The newly identified FOXA1-AR interaction will help further elucidate the molecular mechanisms underlying EC progression and suggests that FOXA1 and AR are potential targets for EC treatment.
This work was supported by National Natural Science Foundation of China (No. 81072139, No.81172476) and the Young Scientific Research Project of Shanghai Municipal Health Bureau (No.20124Y045). We thank Dr. Yuyang Zhao for providing us with the plasmid PWP1/GFP/Neo-AR and its negative control PWP1/GFP/Neo (Department of Urology, Shanghai First People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China). We also thank Dr. Xin Luo, who implemented apparatus and reagent management in the laboratory.
- Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983, 15: 10-17. 10.1016/0090-8258(83)90111-7.View ArticlePubMed
- Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA, Cancer Genome Atlas Research Network: Integrated genomic characterization of endometrial carcinoma. Nature. 2013, 497: 67-73. 10.1038/nature12113.View ArticlePubMed
- Gadducci A, Cosio S, Genazzani AR: Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol. 2006, 58: 242-256. 10.1016/j.critrevonc.2005.11.002.View ArticlePubMed
- Ito K, Suzuki T, Akahira J, Moriya T, Kaneko C, Utsunomiya H, Yaegashi N, Okamura K, Sasano H: Expression of androgen receptor and 5α-reductases in the human normal endometrium and it’s disorders. Int J Cancer. 2002, 99: 652-657. 10.1002/ijc.10394.View ArticlePubMed
- Horie K, Takakura K, Imai K, Liao S, Mori T: Immunohistochemical localization of androgen receptor in the human endometrium, decidua, placenta and pathological conditions of the endometrium. Hum Reprod. 1992, 7: 1461-1466.PubMed
- Hu YC, Wang PH, Yeh S, Wang RS, Xie C, Xu Q, Zhou X, Chao HT, Tsai MY, Chang C: Subfertility and defective folliculogenesis in female mice lacking androgen receptor. Proc Natl Acad Sci USA. 2004, 101: 11209-11214. 10.1073/pnas.0404372101.PubMed CentralView ArticlePubMed
- Carlsson P, Mahlapuu M: Forkhead transcription factors: key players in development and metabolism. Dev Biol. 2002, 250: 1-23. 10.1006/dbio.2002.0780.View ArticlePubMed
- Kaestner KH: The FoxA factors in organogenesis and differentiation. Curr Opin Genet Dev. 2010, 20: 527-532. 10.1016/j.gde.2010.06.005.PubMed CentralView ArticlePubMed
- Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS, Brown M: FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell. 2008, 132: 958-970. 10.1016/j.cell.2008.01.018.PubMed CentralView ArticlePubMed
- Gao N, Zhang J, Rao MA, Case TC, Mirosevich J, Wang Y, Jin R, Gupta A, Rennie PS, Matusik RJ: The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol. 2003, 17: 1484-1507. 10.1210/me.2003-0020.View ArticlePubMed
- Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, Sankila A, Turunen JP, Lundin M, Konsti J, Vesterinen T, Nordling S, Kallioniemi O, Hautaniemi S, Jänne OA: Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 2011, 30: 3962-3976. 10.1038/emboj.2011.328.PubMed CentralView ArticlePubMed
- Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG, Carroll JS: Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 2011, 30: 3019-3027. 10.1038/emboj.2011.216.PubMed CentralView ArticlePubMed
- Axelson H: Notch signaling and cancer: emerging complexity. Semin Cancer Biol. 2004, 14: 317-319. 10.1016/j.semcancer.2004.04.010.View ArticlePubMed
- Qiao L, Wong BC: Role of Notch signaling in colorectal cancer. Carcinogenesis. 2009, 30: 1979-1986. 10.1093/carcin/bgp236.View ArticlePubMed
- Rose SL: Notch signaling pathway in ovarian cancer. Int J Gynecol Cancer. 2009, 19: 564-566. 10.1111/IGC.0b013e3181a12ed2.View ArticlePubMed
- De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A, Kopan R: A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999, 398: 518-522. 10.1038/19083.View ArticlePubMed
- Wei Y, Zhang Z, Liao H, Wu L, Wu X, Zhou D, Xi X, Zhu Y, Feng Y: Nuclear estrogen receptor-mediated Notch signaling and GPR30-mediated PI3K/AKT signaling in the regulation of endometrial cancer cell proliferation. Oncol Rep. 2012, 27: 504-510.PubMed
- Bao W, Wang HH, Tian FJ, He XY, Qiu MT, Wang JY, Zhang HJ, Wang LH, Wan XP: A TrkB-STAT3-miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells. Mol Cancer. 2013, 12: 155-10.1186/1476-4598-12-155.PubMed CentralView ArticlePubMed
- Ni M, Chen Y, Fei T, Li D, Lim E, Liu XS, Brown M: Amplitude modulation of androgen signaling by c-MYC. Genes Dev. 2013, 27: 734-748. 10.1101/gad.209569.112.PubMed CentralView ArticlePubMed
- Yazawa T, Kawabe S, Kanno M, Mizutani T, Imamichi Y, Ju Y, Matsumura T, Yamazaki Y, Usami Y, Kuribayashi M, Shimada M, Kitano T, Umezawa A, Miyamoto K: Androgen/androgen receptor pathway regulates expression of the genes for cyclooxygenase-2 and amphiregulin in periovulatory granulosa cells. Mol Cell Endocrinol. 2013, 369: 42-51. 10.1016/j.mce.2013.02.004.View ArticlePubMed
- Yoshida K, He PJ, Yamauchi N, Hashimoto S, Hattori MA: Up-regulation of circadian clock gene Period 2 in the prostate mesenchymal cells during flutamide-induced apoptosis. Mol Cell Biochem. 2010, 335: 37-45. 10.1007/s11010-009-0238-7.View ArticlePubMed
- Li Z, Tuteja G, Schug J, Kaestner KH: Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell. 2012, 148: 72-83. 10.1016/j.cell.2011.11.026.PubMed CentralView ArticlePubMed
- Dai R, Yan D, Li J, Chen S, Liu Y, Chen R, Duan C, Wei M, Li H, He T: Activation of PKR/eIF2α signaling cascade is associated with dihydrotestosterone-induced cell cycle arrest and apoptosis in human liver cells. J Cell Biochem. 2012, 113: 1800-1808.View ArticlePubMed
- Lin L, Miller CT, Contreras JI, Prescott MS, Dagenais SL, Wu R, Yee J, Orringer MB, Misek DE, Hanash SM, Glover TW, Beer DG: The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Res. 2002, 62: 5273-5279.PubMed
- Jain RK, Mehta RJ, Nakshatri H, Idrees MT, Badve SS: High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology. 2011, 58: 766-772. 10.1111/j.1365-2559.2011.03796.x.View ArticlePubMed
- Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS: Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009, 28: 3526-3536. 10.1038/onc.2009.211.PubMed CentralView ArticlePubMed
- Song Y, Washington MK, Crawford HC: Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res. 2010, 70: 2115-2125. 10.1158/0008-5472.CAN-09-2979.PubMed CentralView ArticlePubMed
- Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS: FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet. 2011, 43: 27-33. 10.1038/ng.730.PubMed CentralView ArticlePubMed
- Sano M, Aoyagi K, Takahashi H, Kawamura T, Mabuchi T, Igaki H, Tachimori Y, Kato H, Ochiai A, Honda H, Nimura Y, Nagino M, Yoshida T, Sasaki H: Forkhead box A1 transcriptional pathway in KRT7-expressing esophageal squamous cell carcinomas with extensive lymph node metastasis. Int J Oncol. 2010, 36: 321-330.PubMed
- Nucera C, Eeckhoute J, Finn S, Carroll JS, Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, Pontecorvi A, Nose V, Loda M, Brown M: FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res. 2009, 15: 3680-3689. 10.1158/1078-0432.CCR-08-3155.View ArticlePubMed
- Abe Y, Ijichi N, Ikeda K, Kayano H, Horie-Inoue K, Takeda S, Inoue S: Forkhead box transcription factor, forkhead box A1, shows negative association with lymph node status in endometrial cancer, and represses cell proliferation and migration of endometrial cancer cells. Cancer Sci. 2012, 103: 806-812. 10.1111/j.1349-7006.2012.02201.x.View ArticlePubMed
- De Marco P, Bartella V, Vivacqua A, Lappano R, Santolla MF, Morcavallo A, Pezzi V, Belfiore A, Maggiolini M: Insulin-like growth factor-I regulates GPER expression and function in cancer cells. Oncogene. 2013, 32: 678-688. 10.1038/onc.2012.97.View ArticlePubMed
- Hackenberg R, Hawighorst T, Hild F, Schulz KD: Establishment of new epithelial carcinoma cell lines by blocking monolayer formation. J Cancer Res Clin Oncol. 1997, 123: 669-673. 10.1007/s004320050122.View ArticlePubMed
- Jiang F, Liu T, He Y, Yan Q, Chen X, Wang H, Wan X: MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. BMC Cancer. 2011, 11: 425-10.1186/1471-2407-11-425.PubMed CentralView ArticlePubMed
- Sisci D, Maris P, Cesario MG, Anselmo W, Coroniti R, Trombino GE, Romeo F, Ferraro A, Lanzino M, Aquila S, Maggiolini M, Mauro L, Morelli C, Andò S: The estrogen receptor α is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness. Cell Cycle. 2013, 12: 3405-3420.PubMed CentralView ArticlePubMed
- Jongen VH, Sluijmer AV, Heineman MJ: The postmenopausal ovary as an androgen-producing gland; hypothesis on the etiology of endometrial cancer. Maturitas. 2002, 43: 77-85. 10.1016/S0378-5122(02)00140-8.View ArticlePubMed
- Sasaki M, Sakuragi N, Dahiya R: The CAG repeats in exon 1 of the androgen receptor gene are significantly longer in endometrial cancer patients. Biochem Biophys Res Commun. 2003, 305: 1105-1108. 10.1016/S0006-291X(03)00883-0.View ArticlePubMed
- Sahlin L, Norstedt G, Eriksson H: Androgen regulation of the insulin-like growth factor-I and the estrogen receptor in rat uterus and liver. J Steroid Biochem Mol Biol. 1994, 51: 57-66. 10.1016/0960-0760(94)90115-5.View ArticlePubMed
- Cirillo LA, Zaret KS: An early developmental transcription factor complex that is more stable on nucleosome core particles than on free DNA. Mol Cell. 1999, 4: 961-969. 10.1016/S1097-2765(00)80225-7.View ArticlePubMed
- Laganière J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguère V: From the Cover: location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci U S A. 2005, 102: 11651-11656. 10.1073/pnas.0505575102.PubMed CentralView ArticlePubMed
- Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, Reich D, Yan C, Khalid O, Kantoff P, Oh W, Manak JR, Berman BP, Henderson BE, Frenkel B, Haiman CA, Freedman M, Tanay A, Coetzee GA: Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet. 2009, 5: e1000597-10.1371/journal.pgen.1000597.PubMed CentralView ArticlePubMed
- Zang S, Ji Ch QX, Dong X, Ma D, Ye J, Ma R, Dai J, Guo D: A study on Notch signaling in human breast cancer. Neoplasma. 2007, 54: 304-310.PubMed
- Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH: Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther. 2006, 5: 483-493.View ArticlePubMed
- Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ: Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005, 11: 6422-6430. 10.1158/1078-0432.CCR-05-0508.View ArticlePubMed
- Catalano S, Giordano C, Rizza P, Gu G, Barone I, Bonofiglio D, Giordano F, Malivindi R, Gaccione D, Lanzino M, De Amicis F, Andò S: Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation. J Cell Physiol. 2009, 218: 490-500. 10.1002/jcp.21622.View ArticlePubMed
- Rutanen EM, Nyman T, Lehtovirta P, Ammälä M, Pekonen F: Suppressed expression of insulin-like growth factor binding protein-1 mRNA in the endometrium: a molecular mechanism associating endometrial cancer with its risk factors. Int J Cancer. 1994, 59: 307-312. 10.1002/ijc.2910590303.View ArticlePubMed
- Matsushima-Nishiu M, Unoki M, Ono K, Tsunoda T, Minaguchi T, Kuramoto H, Nishida M, Satoh T, Tanaka T, Nakamura Y: Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. Cancer Res. 2001, 61: 3741-3749.PubMed
- Huang KT, Pavlides SC, Lecanda J, Blank SV, Mittal KR, Gold LI: Estrogen and progesterone regulate p27kip1 levels via the ubiquitin-proteasome system: pathogenic and therapeutic implications for endometrial cancer. PLoS One. 2012, 7: e46072-10.1371/journal.pone.0046072.PubMed CentralView ArticlePubMed
- Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J: Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2001, 19: 364-367.PubMed
- Day JM, Purohit A, Tutill HJ, Foster PA, Woo LW, Potter BV, Reed MJ: The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy. Ann N Y Acad Sci. 2009, 1155: 80-87. 10.1111/j.1749-6632.2008.03677.x.View ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/78/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.